Menon Lakshmi P, Weinstein Robert S
Division of Endocrinology and Metabolism, Center for Osteoporosis and Metabolic Bone Diseases, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America.
Division of Endocrinology and Metabolism, Center for Osteoporosis and Metabolic Bone Diseases, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America.
Bone. 2020 Feb;131:115137. doi: 10.1016/j.bone.2019.115137. Epub 2019 Nov 19.
Autosomal dominant hypophosphatemic rickets (ADHR) is remarkable among the hypophosphatemic rickets syndromes for its variable age of presentation and periods of quiescence during which serum phosphate and fibroblast growth factor 23 (FGF 23) levels are normal without therapy. In contrast, hypophosphatemia in X-linked hypophosphatemic rickets (XLH) manifests soon after birth and requires lifelong therapy. This suggests that there are environmental factors which can alter FGF 23 activity in ADHR but not in XLH. We present an adult with ADHR in whom resolution of hypophosphatemia was achieved by correcting iron deficiency without the need for phosphate supplementation. Serial iron and FGF 23 levels revealed an inverse relationship (r=-0.79, p<0.04). All patients with ADHR who present with hypophosphatemia and worsening symptoms should be screened for iron deficiency. If iron deficiency is detected, therapy with a combination of calcitriol and iron supplementation should be considered without phosphate supplementation.
常染色体显性低磷性佝偻病(ADHR)在低磷性佝偻病综合征中较为显著,其发病年龄不一,且在未接受治疗的情况下,会出现血清磷酸盐和成纤维细胞生长因子23(FGF 23)水平正常的静止期。相比之下,X连锁低磷性佝偻病(XLH)中的低磷血症在出生后不久就会出现,且需要终身治疗。这表明存在一些环境因素,可改变ADHR中FGF 23的活性,但不会改变XLH中FGF 23的活性。我们报告了一名患有ADHR的成年人,通过纠正缺铁实现了低磷血症的缓解,而无需补充磷酸盐。连续检测铁和FGF 23水平显示出负相关关系(r = -0.79,p < 0.04)。所有出现低磷血症且症状加重的ADHR患者都应筛查是否缺铁。如果检测到缺铁,应考虑联合使用骨化三醇和补充铁剂进行治疗,而无需补充磷酸盐。